Literature DB >> 8635270

Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats.

G R Norton1, G Candy, A J Woodiwiss.   

Abstract

BACKGROUND: A decreased cardiac compliance is a major feature of the cardiomyopathy of diabetes mellitus. Either an increase in the resistance afterload to the LV or an increase in collagen cross-linking induced by the formation of advanced glycosylation end products (AGEs) of collagen may be responsible for the stiff myocardium. To evaluate these hypotheses, we examined the effect of captopril, an afterload-reducing agent, and aminoguanidine, a nucleophilic hydrazine that prevents the accumulation of collagen AGEs, on left ventricular end-diastolic (LVED) compliance after 4 months of streptozotocin (0.26 mmol/kg)-induced diabetes mellitus in rats. METHODS AND
RESULTS: Diabetes mellitus produced a decrease in LV chamber compliance as a result of an increased myocardial stiffness (slope of the linearized LVED stress-LVED strain relation [unitless]: diabetes mellitus, 47+/-4; control, 27+/-3; P<.001) and an increase in blood pressure as a result of an elevated vascular resistance. LV end-systolic elastance was unaltered by diabetes mellitus. The stiff myocardium was not associated with changes in the myocardial collagen volume fraction or total hydroxyproline concentration but was associated with an increased myocardial collagen fluorescence (fluorescence units/microg hydroxyproline) (diabetes mellitus, 11+/-1.1; control, 6.6+/-0.7; P<.01). Captopril therapy (0.22 mmol x kg(-1) x d(-1)), despite producing a decrease in blood pressure through alterations in vascular resistance, failed to decrease myocardial stiffness in rats with diabetes mellitus. Alternatively, administration of aminoguanidine (7.35 mmol x kg(-1) x d(-1)) prevented both the enhanced myocardial collagen fluorescence (7.1+/-1.2) and the increased slope of the linearized LVED stress-LVED strain relation (29+/-2) but did not change markers of blood glucose control.
CONCLUSIONS: These results demonstrate that diabetes mellitus can produce a stiff myocardium before the development of myocardial fibrosis. The stiff myocardium in the early stages of the development of the cardiomyopathy of diabetes mellitus is not a consequence of an increase in ventricular resistance afterload and in these circumstances is associated with the formation of collagen AGEs.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635270     DOI: 10.1161/01.cir.93.10.1905

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  51 in total

1.  An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness.

Authors:  M Asif; J Egan; S Vasan; G N Jyothirmayi; M R Masurekar; S Lopez; C Williams; R L Torres; D Wagle; P Ulrich; A Cerami; M Brines; T J Regan
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

2.  Pharmacological prevention of cardiovascular aging--targeting the Maillard reaction.

Authors:  Doron Aronson
Journal:  Br J Pharmacol       Date:  2004-07-05       Impact factor: 8.739

3.  Mechanical properties of normal and diseased cerebrovascular system.

Authors:  Ali P Ebrahimi
Journal:  J Vasc Interv Neurol       Date:  2009-04

Review 4.  Glucose-induced cell signaling in the pathogenesis of diabetic cardiomyopathy.

Authors:  Rokhsana Mortuza; Subrata Chakrabarti
Journal:  Heart Fail Rev       Date:  2014-01       Impact factor: 4.214

5.  A cross-link breaker has sustained effects on arterial and ventricular properties in older rhesus monkeys.

Authors:  P V Vaitkevicius; M Lane; H Spurgeon; D K Ingram; G S Roth; J J Egan; S Vasan; D R Wagle; P Ulrich; M Brines; J P Wuerth; A Cerami; E G Lakatta
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-30       Impact factor: 11.205

6.  New Peroxisome Proliferator-Activated Receptor Agonist (GQ-11) Improves Wound Healing in Diabetic Mice.

Authors:  Jacqueline C Silva; Marina G R Pitta; Ivan R Pitta; Timothy J Koh; Dulcineia S P Abdalla
Journal:  Adv Wound Care (New Rochelle)       Date:  2019-08-09       Impact factor: 4.730

7.  Effects of a new advanced glycation inhibitor, LR-90, on mitigating arterial stiffening and improving arterial elasticity and compliance in a diabetic rat model: aortic impedance analysis.

Authors:  S Satheesan; J L Figarola; T Dabbs; S Rahbar; R Ermel
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

8.  Early and intermediate Amadori glycosylation adducts, oxidative stress, and endothelial dysfunction in the streptozotocin-induced diabetic rats vasculature.

Authors:  L Rodríguez-Mañas; J Angulo; S Vallejo; C Peiró; A Sánchez-Ferrer; E Cercas; P López-Dóriga; C F Sánchez-Ferrer
Journal:  Diabetologia       Date:  2003-03-12       Impact factor: 10.122

9.  Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report.

Authors:  Sergio Raposeiras-Roubín; Bruno K Rodiño-Janeiro; Beatriz Paradela-Dobarro; Lilian Grigorian-Shamagian; José M García-Acuña; Pablo Aguiar-Souto; Michel Jacquet-Hervet; María V Reino-Maceiras; Ezequiel Alvarez; José R González-Juanatey
Journal:  Cardiovasc Diabetol       Date:  2012-08-21       Impact factor: 9.951

Review 10.  The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease.

Authors:  Shi Fang Yan; Ravichandran Ramasamy; Ann Marie Schmidt
Journal:  Expert Rev Mol Med       Date:  2009-03-12       Impact factor: 5.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.